Overall, while immunotherapy provides a valuable addition to the treatment of esophageal cancer, addressing issues such as PD-L1 repression assessment and cost-effectiveness is essential to optimize its clinical use and maximize its impact on patient outcomes. This evidence concerns the gene CD274 and esophageal cancer.